Johnson Pharmacare Ltd - 532154 - Outcome Of Meeting Of Board Of Directors Held On Wednesday, 27Th May, 2026 At Pursuant To Regulation 30 Of The
SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Johnson Pharmacare's FY26 financial statements received a qualified audit opinion, with auditors noting non-provision of interest on loans, non-compliance with Ind AS, and internal control deficiencies. The company explicitly stated its inability to meet liabilities and reported a significant cash loss of Rs. 111.23 cr for the year. Additionally, it faces non-compliance with RBI regulations for NBFC/CIC criteria.
Jun 01 2026 13:48:10
Johnson Pharmacare Ltd - 532154 - Disclosure Of Related Party Transaction Pursuant To Regulation 23(9) Of Securities And Exchange Board Of India (Listing Obligation And Disclosure Requirements) Regulations, 2015.
Johnson Pharmacare has confirmed that it did not enter into any related party transactions during the fiscal year ended March 31, 2026. This disclosure fulfills the company's compliance obligations under SEBI Regulation 23(9).
May 27 2026 19:57:26
Johnson Pharmacare Ltd - 532154 - Board Meeting Outcome for Outcome Of Meeting Of Board Of Directors Held On Wednesday, 27Th May, 2026 At Pursuant To Regulation 30 Of The
SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Johnson Pharmacare's board approved FY26 audited financial results, reporting a net loss of ₹55.73 crores and revenue of ₹1.58 crores. Auditors issued a qualified opinion, highlighting significant internal control deficiencies and non-compliance with IND-AS, also noting the company's inability to meet liabilities. Two directors resigned.
May 27 2026 19:46:28
Johnson Pharmacare Ltd - 532154 - Board Meeting Intimation for Prior Intimation Of Board Meeting For Approval Of Audited Financial Results For The Quarter & Year Ended On 31St March, 2026.
Johnson Pharmacare will hold a board meeting on May 27, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. This meeting will finalize the company's financial performance for the last quarter and full fiscal year.
May 22 2026 19:08:58
Read More